Ya-Chen Tina Shih1, Fabrice Smieliauskas2, Daniel M Geynisman2, Ronan J Kelly2, Thomas J Smith2. 1. Ya-Chen Tina Shih, University of Texas MD Anderson Cancer Center, Houston, TX; Fabrice Smieliauskas, University of Chicago, Chicago, IL; Daniel M. Geynisman, Fox Chase Cancer Center, Philadelphia, PA; Ronan J. Kelly and Thomas J. Smith, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD. yashih@mdanderson.org. 2. Ya-Chen Tina Shih, University of Texas MD Anderson Cancer Center, Houston, TX; Fabrice Smieliauskas, University of Chicago, Chicago, IL; Daniel M. Geynisman, Fox Chase Cancer Center, Philadelphia, PA; Ronan J. Kelly and Thomas J. Smith, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD.
Abstract
PURPOSE: This study sought to define and identify drivers of trends in cost and use of targeted therapeutics among privately insured nonelderly patients with cancer receiving chemotherapy between 2001 and 2011. METHODS: We classified oncology drugs as targeted oral anticancer medications, targeted intravenous anticancer medications, and all others. Using the LifeLink Health Plan Claims Database, we studied and disaggregated trends in use and in insurance and out-of-pocket payments per patient per month and during the first year of chemotherapy. RESULTS: We found a large increase in the use of targeted intravenous anticancer medications and a gradual increase in targeted oral anticancer medications; targeted therapies accounted for 63% of all chemotherapy expenditures in 2011. Insurance payments per patient per month and in the first year of chemotherapy for targeted oral anticancer medications more than doubled in 10 years, surpassing payments for targeted intravenous anticancer medications, which remained fairly constant throughout. Substitution toward targeted therapies and growth in drug prices both at launch and postlaunch contributed to payer spending growth. Out-of-pocket spending for targeted oral anticancer medications was ≤ half of the amount for targeted intravenous anticancer medications. CONCLUSION: Targeted therapies now dominate anticancer drug spending. More aggressive management of pharmacy benefits for targeted oral anticancer medications and payment reform for injectable drugs hold promise. Restraining the rapid rise in spending will require more than current oral drug parity laws, such as value-based insurance that makes the benefits and costs transparent and involves the patient directly in the choice of treatment.
PURPOSE: This study sought to define and identify drivers of trends in cost and use of targeted therapeutics among privately insured nonelderly patients with cancer receiving chemotherapy between 2001 and 2011. METHODS: We classified oncology drugs as targeted oral anticancer medications, targeted intravenous anticancer medications, and all others. Using the LifeLink Health Plan Claims Database, we studied and disaggregated trends in use and in insurance and out-of-pocket payments per patient per month and during the first year of chemotherapy. RESULTS: We found a large increase in the use of targeted intravenous anticancer medications and a gradual increase in targeted oral anticancer medications; targeted therapies accounted for 63% of all chemotherapy expenditures in 2011. Insurance payments per patient per month and in the first year of chemotherapy for targeted oral anticancer medications more than doubled in 10 years, surpassing payments for targeted intravenous anticancer medications, which remained fairly constant throughout. Substitution toward targeted therapies and growth in drug prices both at launch and postlaunch contributed to payer spending growth. Out-of-pocket spending for targeted oral anticancer medications was ≤ half of the amount for targeted intravenous anticancer medications. CONCLUSION: Targeted therapies now dominate anticancer drug spending. More aggressive management of pharmacy benefits for targeted oral anticancer medications and payment reform for injectable drugs hold promise. Restraining the rapid rise in spending will require more than current oral drug parity laws, such as value-based insurance that makes the benefits and costs transparent and involves the patient directly in the choice of treatment.
Authors: Susan O'Brien; Ellin Berman; Hossein Borghaei; Daniel J Deangelo; Marcel P Devetten; Steven Devine; Harry P Erba; Jason Gotlib; Madan Jagasia; Joseph O Moore; Tariq Mughal; Javier Pinilla-Ibarz; Jerald P Radich; Neil P Shah Md; Paul J Shami; B Douglas Smith; David S Snyder; Martin S Tallman; Moshe Talpaz; Meir Wetzler Journal: J Natl Compr Canc Netw Date: 2009-10 Impact factor: 11.908
Authors: Ya-Chen Tina Shih; Patricia A Ganz; Denise Aberle; Amy Abernethy; Justin Bekelman; Otis Brawley; James S Goodwin; Jim C Hu; Deborah Schrag; Jennifer S Temel; Lowell Schnipper Journal: J Clin Oncol Date: 2013-10-14 Impact factor: 44.544
Authors: Nancy L Keating; Haiden A Huskamp; Deborah Schrag; John M McWilliams; Barbara J McNeil; Bruce E Landon; Michael E Chernew; Sharon-Lise T Normand Journal: Med Care Date: 2018-01 Impact factor: 2.983
Authors: Whitney E Zahnd; Melinda M Davis; Jason S Rotter; Robin C Vanderpool; Cynthia K Perry; Jackilen Shannon; Linda K Ko; Stephanie B Wheeler; Cassie L Odahowski; Paige E Farris; Jan M Eberth Journal: Support Care Cancer Date: 2019-04-10 Impact factor: 3.603
Authors: Matthew P Banegas; Jennifer L Schneider; Alison J Firemark; John F Dickerson; Erin E Kent; Janet S de Moor; Katherine S Virgo; Gery P Guy; Donatus U Ekwueme; Zhiyuan Zheng; Alexandra M Varga; Lisa A Waiwaiole; Stephanie M Nutt; Aditi Narayan; K Robin Yabroff Journal: J Cancer Surviv Date: 2019-05-23 Impact factor: 4.442
Authors: Tania Jaber; Steven G Waguespack; Maria E Cabanillas; Mohamed Elbanan; Thinh Vu; Ramona Dadu; Steven I Sherman; Moran Amit; Elmer B Santos; Mark Zafereo; Naifa L Busaidy Journal: J Clin Endocrinol Metab Date: 2018-10-01 Impact factor: 5.958